Adhesion properties of adult T cell leukemia cells.

abstract：:Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead...

journal_title：Leukemia & lymphoma

authors： Bashash D,Ghaffari SH,Mirzaee R,Alimoghaddam K,Ghavamzadeh A

更新日期：2013-03-01 00:00:00

abstract：:Disruptions of pathways of programmed cell death, or apoptosis, are increasingly found in malignant cells of both solid and hematologic neoplasms. Caspases belong to a family of cysteine proteases and have emerged as central regulators of the apoptotic cascade. Despite many and diverse signals that can trigger apoptos...

journal_title：Leukemia & lymphoma

authors： Faderl S,Estrov Z

更新日期：2001-02-01 00:00:00

abstract：:Immune mechanisms superimposed to the myeloablative conditioning regimens exert an additional powerful effect in eradicating leukemia and in achieving immunological control of minimal residual disease. The impact of GVHD-independent GVL has been evaluated to be absent, or near absent, in ALL, about 30% in AML and abou...

journal_title：Leukemia & lymphoma

authors： Marmont AM

更新日期：1993-01-01 00:00:00

abstract：:Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on cre...

journal_title：Leukemia & lymphoma

authors： Chen CI,Cao Y,Trudel S,Reece DE,Kukreti V,Tiedemann R,Prica A,Paul H,Le LW,Levina O,Kakar S,Lau A,Chen H,Chen E

更新日期：2020-08-01 00:00:00

abstract：:Abstract Everolimus (RAD-001) has recently been used as an immunosuppressive drug to treat patients after hematopoietic stem cell transplant (HSCT), thereby reducing cyclosporine-related nephrotoxicity. We studied the immunomodulatory effect of everolimus on mitogen-stimulated and particularly cytomegalovirus (CMV)-sp...

journal_title：Leukemia & lymphoma

authors： Jin N,Malcherek G,Mani J,Zurleit R,Schmitt A,Chen B,Freund M,Ho AD,Schmitt M

更新日期：2014-05-01 00:00:00

abstract：:This study reports an autopsy case of a 53 year-old male with rapidly progressive extra-nodal NK/T-cell lymphoma accompanied with unusual clinical and pathologic features. He was initially presented with localized swelling and tenderness in the right lower extremity and the biopsy from the calf muscle was interpreted ...

journal_title：Leukemia & lymphoma

authors： Min HS,Hyun CL,Paik JH,Jeon YK,Choi G,Park SH,Seo JW,Kim CW

更新日期：2006-02-01 00:00:00

abstract：:Radioimmunotherapy using (90)Y-ibritumomab tiuxetan has predominantly been used in patients with follicular lymphoma, but little is known about its activity in patients with extranodal marginal zone lymphoma of the mucosa associated lymphoid tissue (MALT). A total of six patients progressing/relapsing following conven...

journal_title：Leukemia & lymphoma

authors： Hoffmann M,Troch M,Eidherr H,Traub-Weidinger T,Jonak C,Muellauer L,Raderer M

更新日期：2011-01-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...

journal_title：Leukemia & lymphoma

authors： Arora R,Press RD

更新日期：2017-01-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep mo...

journal_title：Leukemia & lymphoma

authors： Smirnikhina SA,Lavrov AV,Chelysheva EY,Adilgereeva EP,Shukhov OA,Turkina A,Kutsev SI

更新日期：2016-07-01 00:00:00

abstract：:We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (wh...

journal_title：Leukemia & lymphoma

authors： Middeke JM,Teipel R,Röllig C,Stasik S,Zebisch A,Sill H,Kramer M,Scholl S,Hochhaus A,Jost E,Brümmendorf TH,Naumann R,Steffen B,Serve H,Altmann H,Kunzmann V,Einsele H,Parmentier S,Schaich M,Burchert A,Neubauer A,S

更新日期：2021-01-05 00:00:00

abstract：:The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature. We report a 77-year-old white woman in whom these two disorders were diagnosed concomitantly on the basis of peripher...

journal_title：Leukemia & lymphoma

authors： Robak T,Urbańska-Ryś H,Góra-Tybor J,Wawrzyniak E,Korycka A,Bartkowiak J,Kordek R,Polliack A

更新日期：2003-08-01 00:00:00

abstract：:Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

journal_title：Leukemia & lymphoma

authors： Hawley RG,Berger LC

更新日期：1998-05-01 00:00:00

abstract：:Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

journal_title：Leukemia & lymphoma

authors： Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

更新日期：2018-04-01 00:00:00

abstract：:We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rat...

journal_title：Leukemia & lymphoma

authors： Eren R,Karişmaz A,Karataş D,Doğu MH,Altindal Ş,Yokuş O,Suyani E

更新日期：2019-03-01 00:00:00

abstract：:We applied two-step multicolor flow cytometry (FCM) for circulating lymphoma cells in the blood of 20 patients with angioimmunoblastic T-cell lymphoma (AITL) and confirmed neoplastic T-cells in all. Eleven exhibited dim expression of CD3 and 7 lost its expression. The proportion of CD10+ lymphoma cells ranged widely f...

journal_title：Leukemia & lymphoma

authors： Hayashida M,Maekawa F,Chagi Y,Iioka F,Kobashi Y,Watanabe M,Ohno H

更新日期：2020-10-01 00:00:00

abstract：:The recurring translocation t(1;19) (q23;p13) with TCF3-PBX1 rearrangements are uncommon in adult acute lymphoblastic leukemia (ALL), and their prognostic impact remains to be described in the era of modern chemotherapies. We investigated 427 adult patients with newly diagnosed pre-B ALL, 16 (4%) had t(1;19)(q23;p13) ...

journal_title：Leukemia & lymphoma

authors： Yilmaz M,Kantarjian HM,Toruner G,Yin CC,Kanagal-Shamanna R,Cortes JE,Issa G,Short NJ,Khoury JD,Garcia-Manero G,Ravandi F,Kadia T,Konopleva M,Wierda WG,Jain N,Estrov Z,Sasaki K,Pierce S,O'Brien SM,Jabbour EJ

更新日期：2021-01-01 00:00:00

abstract：:Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

journal_title：Leukemia & lymphoma

authors： Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

更新日期：2006-10-01 00:00:00

abstract：:Donor T cells have a critical role in promoting engraftment after allogeneic bone marrow transplantation (BMT), but also cause graft versus host disease (GVHD). Ex vivo T cell depletion has been an effective strategy to reduce GVHD but has been associated with impaired alloengraftment and host immunity. Using an MHC-m...

journal_title：Leukemia & lymphoma

authors： Drobyski WR,Gendelman M

更新日期：2002-10-01 00:00:00

abstract：:A review of recent information on the expression and the ATRA-driven modulation of cell surface adhesion molecules of acute myelogenous leukemia blast cells is presented. Cytofluorometric studies on fresh blast cells have demonstrated that CD11a, CD11b CD11c, CD15, CD45RO and CD54 expression is significantly lower in ...

journal_title：Leukemia & lymphoma

authors： Di Noto R,Lo Pardo C,Schiavone EM,Ferrara F,Manzo C,Vacca C,Del Vecchio L

更新日期：1996-04-01 00:00:00

abstract：:The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-ce...

journal_title：Leukemia & lymphoma

authors： Bhat SA,Woyach JA

更新日期：2020-03-01 00:00:00

abstract：:The aim of the present study was to evaluate the feasibility and response of the Dexa-BEAM regimen as a salvage therapy followed by high-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBCST) in responding patients with high-grade relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL)....

journal_title：Leukemia & lymphoma

authors： Reiser M,Josting A,Dias Wickramanayake P,Draube A,Scheid C,Tesch H,Wolf J,Diehl V,Engert A

更新日期：1999-04-01 00:00:00

abstract：:We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

journal_title：Leukemia & lymphoma

authors： Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

更新日期：2008-04-01 00:00:00

abstract：:Interleukin-1 receptor type 1 (IL-1R), IL-2 receptor alpha subunit (IL-2R) and IL-6 receptor alpha subunit (IL-6R) mRNA expression in peripheral blood mononuclear cells (PBMC) in 17 patients who underwent allogeneic bone marrow transplantation (allo BMT) and 2 patients who underwent autologous transplantation were ana...

journal_title：Leukemia & lymphoma

authors： Tanaka J,Imamura M,Kasai M,Zhu X,Kobayashi S,Hashino S,Higa T,Sakurada K,Asaka M

更新日期：1995-10-01 00:00:00

abstract：:The purpose of this study was to explore the characteristics and functions of BH3-only proteins Puma, Noxa and Bim in the prognosis, therapy and drug resistance of chronic lymphocytic leukemia (CLL). Puma, Noxa and Bim mRNAs were evaluated by real-time quantitative reverse transcriptase-polymerase chain reaction, and ...

journal_title：Leukemia & lymphoma

authors： Zhu HJ,Liu L,Fan L,Zhang LN,Fang C,Zou ZJ,Li JY,Xu W

更新日期：2013-12-01 00:00:00

abstract：:We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in...

journal_title：Leukemia & lymphoma

authors： Badar T,Hamadani M,Bachanova V,Maddocks KJ,Umyarova E,Chavez JC,Epperla N,Chhabra S,Xavier AC,Karmali R,Salhab M,Reddy N,Glenn MJ,Hernandez-Ilizaliturri FJ,Flowers CR,Evens AM,Zhou Z,Lansigan F,Barta SK,Cohen JB,F

更新日期：2019-04-01 00:00:00

abstract：:BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also at lower frequencies in hematological malignancies. To assess the potential role of BRAF, we have sequenced exons 11 and 15 of BRAF in 138 cases with chronic lymphocytic leukemia (CLL) and 32 cases of B-cell prolymphoc...

journal_title：Leukemia & lymphoma

authors： Jebaraj BM,Kienle D,Bühler A,Winkler D,Döhner H,Stilgenbauer S,Zenz T

更新日期：2013-06-01 00:00:00

abstract：:Immunophenotypic analysis was performed in 53 cases of B chronic lymphocytic leukemia using a large panel of monoclonal antibodies recognizing B, T, activation and myeloid antigens. Our results showed four patterns of reactivity: (a) several molecules were constantly expressed: CD19, CD20, CD24, CD37, HLA-DR, mu heavy...

journal_title：Leukemia & lymphoma

authors： Legac E,Chastang C,Binet JL,Michel A,Debre P,Merle-Beral H

更新日期：1991-01-01 00:00:00

abstract：:A 55-year-old Jewish patient was simultaneously diagnosed as having Gaucher's disease and IgA multiple myeloma. Serum protein electrophoresis and immunoelectrophoresis showed two different IgA kappa type monoclonal spikes. After four years of observation, a rapid fatal course of disease developed together with express...

journal_title：Leukemia & lymphoma

authors： Shvidel L,Hurwitz N,Shtalrid M,Zur S,Oliver O,Berrebi A

更新日期：1995-12-01 00:00:00

abstract：:Contemporary intensive therapies are effective for the majority of pediatric T-lineage acute lymphoblastic leukemia (ALL) patients, thus current challenge is to identify patients who may benefit from alternative treatment modalities. Previously, we demonstrated that human leukemic cell growth in the severe combined im...

journal_title：Leukemia & lymphoma

authors： Uckun FM,Waurzyniak BJ,Sather HN,Sensel MG,Chelstrom L,Nachman J,Gaynon PS,Bostrom B,Ek O,Sarquis M,Steinherz PG,Reaman GH

更新日期：1999-02-01 00:00:00

abstract：:Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM

更新日期：2006-03-01 00:00:00